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Abstract
Madurella mycetomatis is the main causative organism of eumycetoma, a persistent, progressive granulomatous infection.
After subcutaneous inoculation M. mycetomatis organizes itself in grains inside a granuloma with excessive collagen
accumulation surrounding it. This could be contributing to treatment failure towards currently used antifungal agents. Due
to their pivotal role in tissue remodelling, matrix metalloproteinases-2 (MMP-2) and 9 (MMP-9) or tissue inhibitor of
metalloproteinases (TIMP) might be involved in this process. Local MMP-2 and MMP-9 expression was assessed by
immunohistochemistry while absolute serum levels of these enzymes were determined in mycetoma patients and healthy
controls by performing ELISAs. The presence of active MMP was determined by gelatin zymography. We found that both
MMP-2 and MMP-9 are expressed in the mycetoma lesion, but the absolute MMP-2, -9, and TIMP-1 serum levels did not
significantly differ between patients and controls. However, active MMP-9 was found in sera of 36% of M. mycetomatis
infected subjects, whereas this active form was absent in sera of controls (P,0.0001). MMP-2, MMP-9, and TIMP-1
polymorphisms in mycetoma patients and healthy controls were determined through PCR-RFLP or sequencing. A higher T
allele frequency in TIMP-1 (+372) SNP was observed in male M. mycetomatis mycetoma patients compared to controls. The
presence of active MMP-9 in mycetoma patients suggest that MMP-9 is activated or synthesized by inflammatory cells upon
M. mycetomatis infection. Inhibiting MMP-9 activity with doxycycline could prevent collagen accumulation in mycetoma,
which in its turn might make the fungus more accessible to antifungal agents.
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Introduction
Madurella mycetomatis is the most prevalent causative organism of
eumycetoma, a persistent, progressive granulomatous infection
involving subcutaneous tissues and bones [1]. Mycetoma lesions
are characterized by subcutaneous masses, sinuses and fungal
grains, which commonly progress under inappropriate treatment
resulting in deformation and disabilities of infected body parts [1].
To treat eumycetoma, a combination of surgery and treatment
with antifungal agents is required [2]. Treatment with the
currently used antifungal agents, ketoconazole and itraconazole,
only facilitates surgical removal of mycetoma lesions as they
induce encapsulation of the fungal grain with fibrous tissue [3,4].
Encapsulation of the fungal grain by excessive collagen
accumulation could be contributing to the in vivo observed
treatment failure towards antifungal agents [1,2,5]. Collagen
accumulation occurs due to a disrupted equilibrium of extracel-
lular matrix (ECM) synthesis and degradation in which Matrix
Metalloproteinases (MMPs) and Tissue Inhibitors of Matrix
Metalloproteinases (TIMPs) play a pivotal role [6]. MMPs are
classified into distinct groups according to their substrate
specificity: collagenases (MMP-1, -8, -13), gelatinases (MMP-2,
-9), stromelysins (MMP-3, -10, -11), matrilysin (MMP-7, -26),
macrophage metalloestase (MMP-12), and membrane-type MMP
(MMP-14 to MMP-25) [6]. MMP-2 and MMP-9 have the ability
to degrade a variety of ECM constituents (e.g. gelatin, elastin, and
various types of collagen) [6,7]. Since both MMP-2 and MMP-9
are zymogens, proteolytic activation is prerequisite to become
completely active [7]. Although it seems paradoxical, inhibition of
MMP by a synthetic inhibitor decreased collagen accumulation in
peritoneal sclerosis rats and bleomycin-induced pulmonary fibrotic
rats [8,9]. In addition, accumulation of collagen is correlated with
MMP-2 or MMP-9 in several pathological conditions such as
atherosclerosis [10], cardiac fibrosis in diabetic patients [11], and
granulomatous fibrosis of rats with Angiostrongylus cantonensis
infection [12], suggesting that collagen deposition can be
promoted by gelatinases. Although the exact mechanism(s)
explaining these observations have to be clarified, it is hypothe-
sized that MMPs induce de novo ECM accumulation through its
digestion of ECM constituents. Another explanation might be that
MMPs provoke collagen accumulation via another pathway than
ECM digestion.
Neither TIMP-1 nor MMP-2 and MMP-9 have been described
to be involved in mycetoma pathogenesis. In this study, it is
determined if MMP-2 and MMP-9 were expressed locally in the
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lesion by immunohistochemistry. Furthermore, MMP activity and
absolute levels of MMP-2, MMP-9, and TIMP-1 in sera were
assessed in both mycetoma patients and healthy endemic controls.
In addition, polymorphisms in promoter regions of MMP-2,
MMP-9, and TIMP-1 were compared in both groups. The results
obtained show that MMP-9 is associated with mycetoma.
Materials and Methods
Subjects
Genomic DNA of 125 M. mycetomatis infected patients from
Sudan (72.8% male; 27.2% female) and 103 healthy endemic
controls without M. mycetomatis infection (73.8% male; 26.2%
female) were used for genotyping. Sera from another 44 male
Sudanese M. mycetomatis mycetoma patients and 44 male healthy
endemic controls were used to determine levels of MMP-2, MMP-
9, and TIMP-1 and to determine gelatinolytic activity. Tissue
sections from the foot were obtained in 1998 from Sudanese
patients with M. mycetomatis infection. The patients’ demographic
characteristics were recorded and that included gender, duration
of disease, lesion size and site of infection.
Sirius red staining
To localize collagen fibres, tissue sections of 8 M. mycetomatis
infected subjects were stained with Sirius red staining and
subsequently photographed.
Immunohistochemical staining
Immunohistochemical staining was used to assess whether
MMP-2 and MMP-9 are expressed around the fungal grain.
Deparaffinised tissue sections of the same 8 M. mycetomatis infected
subjects used for the Sirius red staining were treated with 0.3%
hydrogen peroxidase for 30 minutes to quench endogenous
peroxidase activity. To inhibit aspecific binding of primary
antibodies, specimens were incubated for 1 hour with 2% normal
goat serum in PBST (0.05% Tween20 (Sigma, Zwijndrecht, The
Netherlands) in PBS). Tissue sections were incubated overnight at
4uC with primary antibodies against MMP-2 (40 mg/ml; IM33
Calbiochem) and MMP-9 (40 mg/ml; IM09L Calbiochem). After
1 hour incubation with goat anti-mouse IgG HRP-conjugated
antibody (1:200; Dako, Heverlee, Belgium) at RT, immunoreac-
tivity was visualized using 3-amino-9-ethyl-carbazole (AEC;
Sigma, Zwijndrecht, The Netherlands). Mayer’s hematoxylin
(Sigma, Zwijndrecht, The Netherlands) was used for counterstain-
ing. As a negative control, tissues were stained without the primary
antibodies being used.
ELISA
Absolute serum levels of MMP-2 and MMP-9 in serum of M.
mycetomatis infected patients (n = 36) and healthy controls (n = 36)
were determined utilizing Human MMP-2 and Human MMP-9
enzyme-linked immunosorbent assay (ELISA) kits (cat#:
RAB0365, Sigma-Aldrich, Zwijndrecht, The Netherlands; and
cat#: KHC3061, Invitrogen, Breda, The Netherlands). Human
TIMP-1 ELISA kit (Cat#: OK-0163, Assay Biotechnology,
Breda, The Netherlands) was used to assess the serum level of
TIMP-1 in both study populations (n = 44 for both populations).
Experiments were conducted according to the manufactures
instructions.
Gelatin zymography
Gelatinolytic activity in sera of M. mycetomatis infected patients
and healthy endemic controls were determined by gelatin
zymography. One ml serum was electrophoresed under non-
reducing conditions on a 10% SDS-polyacrylamine gel co-
polymerized with 1 mg/ml gelatin (Fluka Analytical, Zwijndrecht,
The Netherlands). As a positive control 0.4 ng activated proen-
zyme MMP-2 and 0.1 ng activated proenzyme MMP-9 (Enzo Life
Sciences, Antwerpen, Belgium) were used. After incubating the gel
four times in 2.5% Triton X-100 (v/v) (Sigma, Zwijndrecht, The
Netherlands) for 15 minutes, the gel was incubated in developing
buffer (50 mM Tris (pH 7.5; Sigma, Zwijndrecht, The Nether-
lands), 200 mM NaCl (Merck, Amsterdam, The Netherlands),
5 mM CaCl2 (Merck, Amsterdam, The Netherlands) and 0.02%
BRIJ35 (Calbiochem, San Diego, USA)) for 65 hours at 37uC.
The gel was stained with 50% methanol (Fisher Scientific,
Landsmeer, The Netherlands), 20% acetic acid (J.T. Baker,
Deventer, The Netherlands), and 0.125% Coomassie Brilliant
Blue R-250 (Sigma, Zwijndrecht, The Netherlands) and destained
with destaining solution (30% methanol and 1% formic acid (J.T.
Baker, Deventer, The Netherlands)) until transparent lysis bands
were visible.
Genotyping of MMP-2, -9, and TIMP-1 polymorphisms
Functional SNPs in promoter regions of MMP-2 (21306 C/T),
MMP-9 (21562 C/T), and TIMP-1 (+372 C/T), associated with
altered transcriptional activity [13–15], were genotyped utilizing
genomic DNA of 125 M. mycetomatis infected patients and 103
healthy controls. To determine MMP-2 (21306 C/T) genotype,
DNA was isolated as described before [16,17] and amplified using
primers 59-CTTCCTAGGCTGGTCCTTACTGA-39 and 59-
CTGAGACCTGAAGAGCTAAAGAGCT-39. The PCR reac-
tion consisted of 40 cycles of 30 s denaturation at 94uC, 30 s
annealing at 58uC and 30 s elongation at 72uC. The genotype of
the resulting amplicon was determined by restriction fragment
length polymorphism (PCR-RFLP) with SphI. To determine the
MMP-9 (21562 C/T) genotype, DNA was amplified using
primers 59-GCCTGGCACATAGTAGGCCC-39 and 59CTT-
CCTAGCCAGCCGGCATC-39. The PCR reaction was similar
to the one described for the MMP-2 (21306 C/T) polymorphism,
only the annealing temperature was changed to 65uC. The
genotype of the resulting amplicon was determined by restriction
Author Summary
Eumycetoma, mainly caused by the fungus Madurella
mycetomatis, is a chronic infection which, without treat-
ment, results in deformation of the infected body part.
Inside the body, the fungus organises itself in grains which
are surrounded by collagen. This collagen could act as a
natural barrier for antifungal agents. Since collagen
modulation is regulated by matrix metalloproteinase-2
(MMP-2), MMP-9 and tissue inhibitors of metalloprotei-
nases (TIMPs), these enzymes could play a role in the
formation of the collagen capsule surrounding the fungal
grain. Indeed, we demonstrated that MMPs were found
surrounding the mycetoma grain and that measurable
levels of both MMPs were found in serum of both
mycetoma patients and healthy controls. Only in myceto-
ma patients the active form MMP-9 was found. The
presence of active MMP-9 in the serum of mycetoma-
patients was not the result of lower levels TIMP-1 but more
likely from differences in allele frequencies in the TIMP-1
gene. In conclusion, our results showed an increased MMP-
9 activity in mycetoma patients. We hypothesize that
inhibition of MMP-9 activity by doxycycline will result in
breakdown of the collagen capsule surrounding the grain,
which in turn will make the entrance of antifungal drugs
into the grain easier.
Active MMP-9 Is Associated with Mycetoma
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fragment length polymorphism (PCR-RFLP) with BfaI. The
TIMP-1 (+372 C/T) genotype was identified by sequencing after
amplification with primers 59-GCACATCACTACCTGCAGTC-
39 and 59-GAAACAAGCCCACGATTTAG-39.
Statistical analysis
Deviation from Hardy-Weinberg equilibrium for each poly-
morphism was calculated by the Pearson’s x2 test. Differences in
categorical variables and continuous variables between M.
mycetomatis infected patients and reference group were tested with
Fisher’s exact or Mann-Whitney test respectively. Statistical
comparisons were carried out using GraphPad Prism 5.0 or
GraphPad InStat 3.0 (GraphPad Software, San Diego California
USA). P,0.05 was considered to be statistically significant.
Ethics statement
Written informed consent was obtained from all participants
and ethical clearance was obtained from Soba University Hospital
Ethical Committee, Khartoum, Sudan.
Results
Excessive collagen deposition surrounds the fungal grain
Collagen accumulation around the fungal grain was assessed by
staining specimens of M. mycetomatis infected subjects by Sirius red.
A representative photomicrograph of a Sirius red stained tissue
section shows that the fungal grain is encapsulated with collagen
deposition (Figure 1b). After this first collagen deposition ring,
often a denser collagen capsule is seen at some distance of the
grain. In that capsule typical collagen fibres are noted.
MMP-2 and MMP-9 are expressed by immune-cells
surrounding the fungal grain
In order to determine if the gelatinases MMP-2 and MMP-9
play a role in the encapsulation of the mycetoma grain, the
presence of these two MMPs was demonstrated by immunohis-
tochemical staining of tissue sections of patients infected with M.
mycetomatis (Figures 1c and 1d). As is seen in figure 1c and 1d, both
MMP-2 and MMP-9 were detectable as red cytoplasmatic staining
in cells, mainly in zone 2 surrounding the grain. In the neutrophil
zone (zone 1), little expression of either metalloproteases was
noted, although in some patients also this zone showed expression
of MMP-2 and MMP-9. Strikingly expression was mainly found in
areas where little collagen deposition was seen. If there was heavy
collagen deposition hardly any MMP-2 and MMP-9 expression
was noted (figure 1). In slides where primary antibodies were
omitted, coloration was absent (not shown).
Active MMP-9 in serum is detectable in mycetoma
patients but not in healthy endemic controls
In order to determine if the MMP-2 and MMP-9 expression
was also found in serum, ELISAs were performed to determine the
concentrations of MMP-2 and MMP-9 in sera of mycetoma
patients and healthy controls. It appeared that MMP-2 was hardly
detected in sera of either patients or controls (Figure 2A, MMP-2
median 0 ng/ml for both groups). There were no differences
between the patients and the healthy controls (Mann-Whitney,
p = 0.42). Also, similar concentrations of MMP-9 were found in
sera of both M. mycetomatis infected patients and controls
(Figure 2B, median concentration 451.6 ng/ml versus 461.2 ng/
ml, respectively; Mann-Whitney, p = 0.57). The drawback by
measuring MMP-2 and MMP-9 concentrations by ELISA is that it
is not possible to distinguish between inactive and active MMP-2
and MMP-9. In order to distinguish between active and inactive
gelatinase in sera of M. mycetomatis infected patients and healthy
endemic controls, gelatin zymography was used. Characteristic
gelatinolytic patterns due to the presence of pro-active and active
forms of MMP-2 and MMP-9 in sera of M. mycetomatis infected
patients and healthy controls are depicted in Figure 3. Active
MMP-9 of 84 kDa was found in sera of 36% of M. mycetomatis
infected subjects, whereas this active form was not present in sera
of the control population (Fisher Exact, p,0.0001). No correlation
was found between the presence of active MMP-9 and lesion size
or disease duration (data not shown). Active MMP-2 (62 kDa) was
absent in both groups. The pro-active forms of MMP-2 and
MMP-9, 72 and 92 kDa respectively, were present in sera of all M.
mycetomatis infected patients and healthy controls. Since mycetoma
patients had more often active MMP-9 in their sera, while the total
amount of MMP-9 (both active and inactive) did not differ, it was
investigated if TIMP-1 levels differed between patients and healthy
endemic controls by ELISA. This was done since TIMP-1 is
known to block protease activity of both MMP-2 and MMP-9. It
appeared that TIMP-1 serum levels of both groups did not
significantly differ (Figure 2C, median 195.8 ng/ml for M.
mycetomatis infected patients vs. 170.0 ng/ml for controls; Mann-
Whitney, p= 0.99). Ratios of MMP-9 to TIMP-1 were compara-
ble and did not reach statistical significance (Figure 2D; Mann-
Whitney, p= 0.59).
The T-allele of the TIMP-1 (+372 C/T) polymorphisms is
associated with mycetoma in males
In order to determine if the difference in activeMMP-9 levels was
the result of genotypic differences between patients and healthy
controls, we determined whether allele frequencies in functional
polymorphisms in MMP-2, MMP-9 and TIMP-1 differed between
M. mycetomatis infected patients and healthy controls by SNP
analyses. All studied genotypes did not show deviation from Hardy-
Weinberg equilibrium (p.0.05). Allele frequencies of MMP-2,
MMP-9, and TIMP-1 polymorphisms were compared between M.
mycetomatis infected patients and healthy controls (Table 1). Since the
TIMP-1 gene is X-chromosome located, genotype analyses were
stratified according to gender.
The allele distributions for MMP-2 (21306 C/T) and MMP-9
(21562 C/T) polymorphisms did not significantly differ between
M. mycetomatis infected subjects and controls (p = 0.39 and p= 1.00
respectively). The T allele frequency in TIMP-1 (+372 C/T)
polymorphism was significantly higher in male M. mycetomatis
infected patients compared to the male reference group (46%
versus 26%) (p = 0.0004). In female M. mycetomatis infected patients
the allelic distribution in TIMP-1(+372 C/T) polymorphism did
not significantly differ with female control subjects (p = 0.53).
Discussion
Eradication of M. mycetomatis mycetoma remains challenging as
in vivo treatment failure towards currently used antifungal agents is
frequently observed. It has been reported that collagen accumu-
lation contributes to limited penetration of chemotherapeutic
agents into the granuloma [18], suggesting that a dense collagen
network might influence drug accessibility. Therefore, diminished
response upon antifungal treatment might be partly caused by
excessive collagen accumulation in the mycetoma lesion. Unrav-
elling the mechanism behind observed changes in tissue architec-
ture around the fungal grain could direct to novel therapeutic
options. In this study we investigated suitable candidates, MMP-2,
MMP-9, and TIMP-1, as they are participants in ECM
remodeling.
Active MMP-9 Is Associated with Mycetoma
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Both MMP-2 and MMP-9 were found to be expressed in the
mycetoma lesion, and both were highly expressed locally
surrounding the fungal grain. Constitutive expression of MMP-2
takes place in various cell types and is barely induced under pro-
inflammatory conditions [19]. Furthermore, one of the character-
istics of mycetoma is that during grain formation high amounts of
neutrophils are recruited to the site of M. mycetomatis infection [17].
MMP-9 is constitutively expressed and stored in high quantities in
granules of neutrophils, and several chemotactic chemokines and
cytokines are able to induce degranulation of MMP-9 containing
granules [20,21]. Furthermore, inflammatory stimuli are able to
upregulate MMP-9 expression in a wide range of inflammatory
cell types, such as lymphocytes, monocytes, and neutrophils
[19,22].
Absolute MMP-2, MMP-9, and TIMP-1 serum levels were
comparable between M. mycetomatis infected patients and healthy
controls and did not reach statistical significance. However, since
the ELISA measured both the pro-active and the active forms of
MMP-2 and MMP-9, these observations have only a limited value.
Therefore, MMP-2 and MMP-9 activity was tested by gelatin
zymography. Despite comparable absolute serum levels in both
groups, MMP-9 activity was significantly higher in the M.
mycetomatis mycetoma population. A higher MMP-9 activation
could be the result of a higher MMP-9 expression or a lower
TIMP-1 expression. TIMP-1 inhibits MMP-9 activity by forming
a 1:1 stoichiometric non-covalent complex [6]. Disruption of
MMP-9:TIMP-1 complexes result in release and activation of
MMP-9. Several other participants in MMP-9 activation have
been described, including protease-based activators (e.g. trypsin
[23] and neutrophil-derived elastase [24]) and other MMPs [21].
Although we only found activated MMP-9 found in mycetoma
patients, there was still a large proportion of the patients in which
we did not find the activated form. Similar findings were reported
for patients with severe sepsis [25]. Only in 10 out of 20 patients
with severe sepsis on the intensive care unit, activated MMP-9 was
found [25]. Again no correlation with disease severity was noted
Figure 1. Collagen deposition and MMP-2 and MMP-9 expression around theM. mycetomatis grain. In this figure a representative picture
of the M. mycetomatis grain insight the subcutaneous tissue from one particular patient is shown. In panel A, a HE staining is performed. The grain (G)
and two different zones surrounding the grain are clearly visible (1,2). Zone 1, representing the neutrophil zone is relatively small around this typical
grain. In zone 2, histocytes, capillaries, lymphocytes, plasma cells, fibroblasts and some macrophages are seen. In panel B, a Sirius red staining of the
same area is shown. As is seen on this slide, collagen (coloured red) is mainly seen within zone 2. In panels C and D, MMP-2 and MMP-9 are detected
by immunohistochemical staining, respectively. MMP-2 and MMP-9 positive cells are stained red, as a counterstaining hematoxylin is used. Relatively
little MMP-2 positive cells were noted in the rim of zone 2, outside the layer where the collagen deposition was seen in panel B. MMP-9 staining was
more heavily. Some cells in zone 2 stained positive for MMP-9, but more positive cells were seen at the rim of this zone (zone 3). No MMP-2
expression was noted in zone 1 surrounding the grain.
doi:10.1371/journal.pntd.0002754.g001
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[25]. Why we measured in one patient active MMP-9 and the
other not is not clear. Several reasons could be attributing. First of
all, we only took one time-point and these time-points differ for
each patient. MMP-9 expression could be dependent on the
disease stadium, although we did not find a correlation with the
disease duration or the size of the lesion, other factors might be
responsible such as if the patient had at the time of sampling
discharging sinuses or not. Furthermore we did not record if the
patient had other infections. Furthermore, it is also plausible that
co-infections could play are role since they are frequently reported
in mycetoma [26] and a correlation between mycetoma and
schistomiasis was also recently reported [27]. Differences in MMP-
9 expression between the M. mycetomatis infected patients
individually and between patients and healthy endemic controls
as a group could also be caused by genetic differences. We
therefore genotyped functional polymorphisms in the promoter
regions of MMP-2 (21306 C/T), MMP-9 (21562 C/T), and
TIMP-1 (+372). While no significant difference in allele distribu-
tions in the MMP-9 (21572 C/T) polymorphism was found, other
SNPs in the promoter region of MMP-9 or MMP-9 itself were not
investigated and could contribute to increased MMP-9 activation
in M. mycetomatis infected patients. In contrast, a genetic difference
between both groups was found for TIMP-1 (+372 SNP). The T
allele frequency in TIMP-1 SNP in male M. mycetomatis infected
patients was significantly higher compared to healthy controls. In
man, T allele associated transcriptional activity of TIMP-1 is lower
than C allele associated transcriptional activity [15], suggesting
that TIMP-1 production and thereby MMP inhibition in these
subjects is reduced. This finding might explain previously reported
male predominance in mycetoma [1]. Due to lower T allele
associated transcriptional activity of TIMP-1, we expected reduced
TIMP-1 serum levels in M. mycetomatis infected subjects, but this
was not the case. However, since mycetoma is a localized
infection, a localized reduction of TIMP-1 could result in higher
Figure 2. Concentrations of MMP-2 (A),MMP-9 (B), TIMP-1 (C), and MMP-9:TIMP-1 ratios (D) in sera of M. mycetomatis infected
subjects and healthy endemic controls. Data is presented as median. Each dot represents the serum concentration or ratio of each (inhibitor of)
metalloproteinases of one patient or healthy control. Significance was determined by Mann-Whitney test.
doi:10.1371/journal.pntd.0002754.g002
Figure 3. MMP activity in sera of M. mycetomatis infected
patients and healthy endemic controls as demonstrated by
gelatine zymography. One ml of serum of each subject was analyzed
for MMP activity. Representative gelatine zymograms of 12 M.
mycetomatis infected subjects (A) and 10 healthy endemic controls
(B) are shown. The pro-active and active forms of MMP-2 and MMP-9 are
marked with arrows. MMP-2: Activated proenzyme MMP-2; MMP-9:
Activated proenzyme MMP-9.
doi:10.1371/journal.pntd.0002754.g003
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MMP-9 levels in the lesion, which, in its turn, could be found in
serum.
In this study we showed that collagen is indeed encapsulating
the grain and MMP-9 is the collagenase activated during M.
mycetomatis infection. The question remains what the exact function
of grain encapsulation is. Is this encapsulation beneficial to the
host, by keeping the M. mycetomatis infection localized and
preventing the spread of infection? Or prevents the collagen
capsule surrounding the fungal grain the penetration of drugs into
the grain? If the latter would be the case, one could consider
adding the antimicrobial agent doxycycline to the currently used
therapeutic strategy. Doxycycline is a potent MMP inhibitor
which is able to reduce MMP-2 and MMP-9 mRNA expression
and MMP-2 production in vitro and thereby attenuates collagen
accumulation in pulmonary fibrosis [28]. By attenuating the
collagen deposition around the grain, ketoconazole and itracon-
azole might be able to better penetrate to the fungus.
In summary, the results obtained in the present study show
increased MMP-9 activity during M. mycetomatis infection, suggest-
ing that MMP-9 is associated with M. mycetomatis mycetoma.
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